FDA Approves First Once-Monthly Injectable Olanzapine for Schizophrenia Treatment
Teva Pharmaceuticals announced FDA approval of Weltruza (olanzapine extended-release injectable suspension) for the treatment of schizophrenia in adults on October 9, 2026.
Key Details
The medication requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS trial data showing efficacy and safety.
Why It Matters
This once-monthly formulation offers improved convenience and potential adherence benefits compared to daily oral antipsychotics for schizophrenia management.
Context
The approval marks the first and only once-monthly subcutaneous injectable olanzapine formulation available in the United States for schizophrenia treatment.
Source: AJMC. This article summarizes the linked reporting and distinguishes announced plans from demonstrated results.